2023
Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets
Warren R, Strober B, Silverberg J, Guttman E, Andres P, Felding J, Tutkunkardas D, Kjøller K, Sommer M, French L. Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets. Journal Of The European Academy Of Dermatology And Venereology 2023, 37: 711-720. PMID: 36478476, DOI: 10.1111/jdv.18812.Peer-Reviewed Original ResearchConceptsPhase 1 trialPhase 2a trialSevere psoriasisAdverse eventsIR formulationPK propertiesWeek 16Psoriasis Area Severity Index (PASI) scorePlacebo-controlled trialSeverity Index scoreHigh-fat mealLow-fat mealPhosphodiesterase 4 inhibitorSimilar PK propertiesImmediate-release formulationGI disordersMR groupPlaceboFood effectPhase 2aIndex scorePsoriasisPharmacokinetic propertiesHealthy participantsMR formulation
2022
Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting
Strober B, Patil D, McLean R, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting. Dermatology And Therapy 2022, 12: 1351-1365. PMID: 35551619, PMCID: PMC9100304, DOI: 10.1007/s13555-022-00740-y.Peer-Reviewed Original ResearchBiologic-naive patientsInvestigator's Global AssessmentBody surface areaClinical outcomesUS real-world settingGlobal assessmentBiologic-experienced patientsEffectiveness of secukinumabMethodsThis observational studyPrior biologic useFirst-line therapyProportion of patientsSeverity Index scoreTreatment of psoriasisSimilar improvementsBiologic experiencePsoriasis RegistryResultsBetween 2015Secukinumab treatmentIGA scoreBiologic useClinical characteristicsPatient characteristicsPsoriasis AreaPatient cohort
2021
Bimekizumab versus Secukinumab in Plaque Psoriasis
Reich K, Warren R, Lebwohl M, Gooderham M, Strober B, Langley R, Paul C, De Cuyper D, Vanvoorden V, Madden C, Cioffi C, Peterson L, Blauvelt A. Bimekizumab versus Secukinumab in Plaque Psoriasis. New England Journal Of Medicine 2021, 385: 142-152. PMID: 33891380, DOI: 10.1056/nejmoa2102383.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisPlaque psoriasisWeek 48Week 16Bimekizumab groupSecukinumab groupPASI scoreInterleukin-17AOral candidiasisGreater skin clearanceInterleukin-17 inhibitorsPASI 100 responsePhase 3b trialSafety of bimekizumabPrimary end pointSeverity Index scoreMonoclonal IgG1 antibodySkin clearanceSevere psoriasisPsoriasis AreaLarge trialsBimekizumabSecukinumabWeek 4Patients
2020
13601 BMS-986165, an oral selective TYK2 inhibitor, in the treatment of moderate to severe psoriasis as assessed by the static Physicians Global Assessment/body surface area composite tool, a clinically useful alternative to the Psoriasis Area and Severity Index score
Gottlieb A, Strober B, Thaci D, Gordon K, Ren H, Kisa R, Wei L, Banerjee S, Merola J. 13601 BMS-986165, an oral selective TYK2 inhibitor, in the treatment of moderate to severe psoriasis as assessed by the static Physicians Global Assessment/body surface area composite tool, a clinically useful alternative to the Psoriasis Area and Severity Index score. Journal Of The American Academy Of Dermatology 2020, 83: ab120. DOI: 10.1016/j.jaad.2020.06.569.Peer-Reviewed Original Research
2017
Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis
Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis. British Journal Of Dermatology 2017, 177: 1562-1574. PMID: 28755394, DOI: 10.1111/bjd.15857.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisBody surface areaABP 501Week 16Adverse eventsAntidrug antibodiesPlaque psoriasisBiosimilar ABP 501New safety signalsPercentage of patientsPhase III trialsSimilar clinical efficacySeverity Index scorePercentage body surface areaLong-term resultsEuropean Medicines AgencyPASI 50PASI improvementWeek 52III trialsPsoriasis AreaAdalimumab patientsImmunogenicity profileClinical efficacyPatient populationCurrent biologic therapies (including IL-17) and monitoring guidelines
Strober B, Wald J. Current biologic therapies (including IL-17) and monitoring guidelines. 2017, 233-240. DOI: 10.1201/9781315119298-23.Peer-Reviewed Original ResearchTuberculin skin testLatent tuberculosisBiologic therapyQuantiFERON-TB Gold testPhase 3 clinical trialsCurrent biologic therapiesInitiation of treatmentSeverity Index scoreInterferon-gamma releaseEfficacy of treatmentHuman monoclonal antibodyMembrane-bound TNFPsoriasis AreaAtypical presentationGamma releaseSkin testThorough historyClinical trialsGold testIndex scoreControl populationMonoclonal antibodiesTNFAdverse effectsTuberculosisClinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Narbutt J, Philipp S, Spelman L, Weglowska J, Zhang N, Strober B. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. Journal Of The American Academy Of Dermatology 2017, 76: 1093-1102. PMID: 28291552, DOI: 10.1016/j.jaad.2016.12.014.Peer-Reviewed Original ResearchConceptsABP 501Week 16Psoriasis AreaClinical similaritiesBiosimilar ABP 501Biosimilars of adalimumabSevere plaque psoriasisDouble-blind studySeverity Index scoreTreatment of patientsAntibody incidencePlaque psoriasisSevere psoriasisAdalimumabIndex scoreEquivalence marginPatientsImmunogenicityConfidence intervalsTreatment differencesPercent improvementPsoriasisSame treatmentBaselineMore improvement
2015
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. New England Journal Of Medicine 2015, 373: 1318-1328. PMID: 26422722, DOI: 10.1056/nejmoa1503824.Peer-Reviewed Original ResearchConceptsPASI 100 response ratesGlobal assessment scoreWeek 12Response rateSevere psoriasisStatic Physician's Global Assessment scorePASI 75 response ratesPhysician Global Assessment scoreRates of neutropeniaSerious infectious episodesPhase 3 studySignificant clinical improvementSeverity Index scoreTreatment of psoriasisEarly clinical studiesAMAGINE-2Brodalumab treatmentSPGA scoreInfectious episodesWeek 52Clinical improvementMaintenance dosePASI scorePsoriasis AreaBrodalumab
2014
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis
Papp K, Menter A, Strober B, Kricorian G, Thompson E, Milmont C, Nirula A, Klekotka P. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. Journal Of The American Academy Of Dermatology 2014, 72: 436-439.e1. PMID: 25553889, DOI: 10.1016/j.jaad.2014.10.026.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisBiologic useHistory of PsAPlaque psoriasisDermatology Life Quality Index responseStatic Physician's Global Assessment scorePhysician Global Assessment scoreSafety of brodalumabPlacebo-controlled studySubgroup of patientsSeverity Index scoreSubpopulation of patientsGlobal assessment scoreSelf-reported historyPrior biologicsTreat populationPsoriasis AreaPsoriatic arthritisWeek 12Subset analysisNovel therapiesBrodalumabLife measuresPatientsPsoriasis
2012
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo‐controlled dose‐ranging study
Papp K, Menter A, Strober B, Langley R, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness J. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo‐controlled dose‐ranging study. British Journal Of Dermatology 2012, 167: 668-677. PMID: 22924949, DOI: 10.1111/j.1365-2133.2012.11168.x.Peer-Reviewed Original ResearchConceptsOral Janus kinase inhibitorSafety of tofacitinibDose-ranging studyJanus kinase inhibitorPlaque psoriasisAdverse eventsWeek 12Mean serum high density lipoproteinPlacebo-controlled dose-ranging studyResponse ratePASI 75 response ratesSevere chronic plaque psoriasisKinase inhibitorsPASI 75 responseTwice daily groupChronic plaque psoriasisSerum high-density lipoproteinSevere plaque psoriasisProportion of patientsSignificant clinical improvementSeverity Index scoreTreatment of psoriasisDose-dependent increaseShort-term treatmentHigh-density lipoprotein
2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
Strober B, Poulin Y, Kerdel F, Langley R, Gu Y, Gupta S, Okun M, Papp K. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study. Journal Of The American Academy Of Dermatology 2011, 64: 671-681. PMID: 21414495, DOI: 10.1016/j.jaad.2010.03.009.Peer-Reviewed Original ResearchConceptsPhysician global assessmentSuboptimal responseSuboptimal therapyWeek 16Global assessmentPhase IIIb trialChronic plaque psoriasisOpen-label designOpen-label studyPrimary end pointPercentage of patientsNB-UVB phototherapySeverity Index scorePsoriasis clinical trialsTreatment of psoriasisDosage taperingIIIb trialPrior therapyPlaque psoriasisPsoriasis AreaPsoriasis flarePsoriasis patientsSafety profilePatient enrollmentClinical trials
2008
Effects of etanercept on C‐reactive protein levels in psoriasis and psoriatic arthritis
Strober B, Teller C, Yamauchi P, Miller J, Hooper M, Yang Y, Dann F. Effects of etanercept on C‐reactive protein levels in psoriasis and psoriatic arthritis. British Journal Of Dermatology 2008, 159: 322-330. PMID: 18503600, DOI: 10.1111/j.1365-2133.2008.08628.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, PsoriaticBiomarkersBody Mass IndexC-Reactive ProteinDouble-Blind MethodEtanerceptFemaleHumansImmunoglobulin GMaleMiddle AgedPsoriasisReceptors, Tumor Necrosis FactorRetrospective StudiesSeverity of Illness IndexTumor Necrosis Factor-alphaConceptsC-reactive proteinBody mass indexEffect of etanerceptCRP levelsPsoriatic arthritisCRP valuesBaseline C-reactive proteinC-reactive protein levelsHigher body mass indexLower body mass indexBaseline CRP valuesBaseline PASI scoreSkin disease activityStatin drug useSevere plaque psoriasisBaseline CRP levelsElevated CRP levelsSeverity Index scoreEtanercept treatmentRegistrational studiesCRP elevationPlaque psoriasisCardiovascular riskDisease activityPASI score
2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Menter A, Tyring S, Gordon K, Kimball A, Leonardi C, Langley R, Strober B, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. Journal Of The American Academy Of Dermatology 2007, 58: 106-115. PMID: 17936411, DOI: 10.1016/j.jaad.2007.09.010.Peer-Reviewed Original ResearchConceptsSevere psoriasisPlacebo-treated patientsSafety of adalimumabChronic plaque psoriasisPercentage of patientsPhase III trialsSeverity Index scorePathogenesis of psoriasisKey proinflammatory cytokinesTumor necrosis factorHuman monoclonal antibodyInterrupted therapyAdalimumab therapyPlaque psoriasisWeek 52III trialsPASI scorePsoriasis AreaActive comparatorClinical efficacyMulticenter studyProinflammatory cytokinesWeek 16Necrosis factorAdalimumab